Factbox: Countries weigh ‘mix and match’ COVID-19 vaccines


A medical employee administers a dose of the “Comirnaty” Pfizer-BioNTech COVID-19 vaccine in a vaccination middle in Paris as a part of the coronavirus illness (COVID-19) vaccination marketing campaign in France, Could 12, 2021. REUTERS/Gonzalo Fuentes

A rising variety of nations are switching to totally different COVID-19 vaccines for second doses amid provide delays and security considerations which have slowed their vaccination campaigns. learn extra

A number of medical research to check the efficacy of switching COVID-19 vaccines are underneath means. learn extra

The next are nations which can be weighing, or have determined to undertake, such an answer:


* Officers stated in Could that individuals who have been inoculated with AstraZeneca’s (AZN.L) COVID-19 shot could also be provided a second dose of one other vaccine, a transfer primarily based on provide considerations in addition to the rise in incidence of uncommon blood clots linked to first doses produced by the Anglo-Swedish drugmaker.


* Chinese language researchers in April have been testing the blending of COVID-19 vaccine doses developed by CanSino Biologics (6185.HK), and a unit of Chongqing Zhifei Organic Merchandise (300122.SZ), based on medical trial registration knowledge.

* China’s prime illness management official stated on April 12 the nation was “formally contemplating” mixing COVID-19 vaccine doses developed with totally different applied sciences to spice up their efficacy.


* Finland’s Institute of Well being and Welfare stated on April 14 that recipients of a primary dose of AstraZeneca’s vaccine who’re aged underneath 65 could get a unique shot for his or her second dose, as authorities warned about delays to the nation’s rollout. learn extra


* France’s prime well being advisory physique Haute Autorite de la Sante (HAS) advisable in April that folks underneath 55 injected with a primary shot of the AstraZeneca vaccine ought to obtain a second dose with a so-called messenger RNA vaccine, though dose-mixing has not but been evaluated in trials. learn extra


* Norway stated on April 23 it could supply those that have obtained a dose of the AstraZeneca vaccine an injection with an mRNA vaccine as their second dose. learn extra


* South Korea stated on Could 20 it could run a mix-and-match trial of COVID-19 vaccines, mixing AstraZeneca doses with these developed by Pfizer and different drugmakers. learn extra


* Spanish Well being Minister Carolina Darias stated on Could 19 the nation would enable folks underneath 60 years previous, who’ve obtained a primary dose of AstraZeneca’s vaccine, to obtain a second dose of both the AstraZeneca shot or Pfizer’s (PFE.N) vaccine. learn extra

* A examine on mixing COVID-19 vaccines, run by Spain’s state-backed Carlos III Well being Institute, discovered that giving a dose of Pfizer’s shot to individuals who have already obtained a primary shot of AstraZeneca’s vaccine is secure and extremely efficient, preliminary outcomes confirmed on Could 18. learn extra


* Sweden’s well being company stated on April 20 that folks underneath 65 years of age, who’ve had one shot of AstraZeneca’s vaccine, can be given a unique vaccine for his or her second dose.


* Britain stated in January it could enable folks to be given a unique vaccine for a second dose on extraordinarily uncommon events, for instance if the primary vaccine was out of inventory. learn extra

* The primary findings of an Oxford College-led examine launched on Could 12 discovered that individuals who obtained Pfizer’s vaccine adopted by a dose of AstraZeneca’s, or vice versa, have been extra prone to report delicate or average frequent post-vaccination signs than in the event that they obtained two of the identical sort. https://bit.ly/3fraZz9

* Novavax (NVAX.O) stated on Could 21 it could participate in a mix-and-match COVID-19 vaccine trial to check the usage of a further vaccine dose from a unique producer as a booster. The trial will begin in June in the UK


* In January, CNBC reported the U.S. Facilities for Illness Management and Prevention (CDC) had up to date its steerage, permitting a mixture of Pfizer/BioNTech’s (22UAy.DE) and Moderna’s (MRNA.O) pictures with a niche of at the very least 28 days between the 2 inoculations, and just for “distinctive conditions”.

Our Requirements: The Thomson Reuters Belief Rules.


Please enter your comment!
Please enter your name here